Larkspur Health (LSPR) to Combine with ZyVersa Therapeutics in $108.9M Deal

Larkspur Health (LSPR) to Combine with ZyVersa Therapeutics in $108.9M Deal

Larkspur Health (NASDAQ:LSPR) has entered into a definitive agreement to combine with specialty biopharmaceutical company ZyVersa at an enterprise value of $108.92 million. Weston, Florida-based ZyVersa is developing clinical and preclinical treatments for a variety of inflammatory diseases affecting the kidneys and nervous system. The combined company is expected to trade on the Nasdaq under the
Read More

To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.